Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang… - The Lancet Infectious …, 2019 - thelancet.com
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang, HM Cheeseman… - 2019 - cabidigitallibrary.org
Background: Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang… - The Lancet. Infectious …, 2019 - europepmc.org
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang, HM Cheeseman… - The Lancet Infectious …, 2019 - Elsevier
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
[引用][C] Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human …
S Abraham, HB Juel, P Bang, HM Cheeseman… - The Lancet Infectious …, 2019 - cir.nii.ac.jp
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with
CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind …
CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind …
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …
S Abraham, HB Juel, P Bang, HM Cheeseman… - cbmr.ku.dk
Background: Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …
worldwide. National screening programmes and antibiotic treatment have failed to decrease …